NEW YORK, May 15, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Intra-Cellular Therapies, Inc. ("Intra-Cellular Therapies") (NASDAQ:ITCI) between August 12, 2014 and April 28, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of New York. To get more information go to:
http://www.zlk.com/pslra-sb/intra-cellular-therapies-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; (2) and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 4, 2016, the Company’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” Then on May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients.
If you suffered a loss in Intra-Cellular Therapies you have until July 11, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions
Samsung Set to Begin HBM4 Production for Nvidia and AMD
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand
ASML’s EUV Monopoly Powers the Global AI Chip Boom
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 



